Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
HilleVax is a biopharmaceutical company developing novel vaccines, primarily targeting norovirus-induced gastroenteritis. Its lead candidate, HIL-214, is a VLP-based vaccine designed to prevent severe AGE caused by norovirus, with ongoing clinical trials in adults and infants. The company leverages proprietary VLP technology, focusing on high-risk populations like children and older adults, aiming to address a global, underserved market with significant health and economic burdens.
This description was generated via AI from an annual report. Updated about 1 year ago.